FDA has approved anti-glioma therapy drugs, including temozolomide (Esteller et al., 2000; Hegi et al., 2004), a DNA alkylation reagent, often used with radiotherapy; bevacizumab, a human monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), and the combination with chemotherapy are related to the long-term survival rate of patients (Vredenburgh et al., 2007; Miller et al., 2008). The gene discussed is VEGFA; the disease is central nervous system cancer.